Buying a Pharmacy: Price, Multiples & SBA Financing 2026

Pharmacy Valuation Multiples: What Buyers Are Paying in 2025–2026

Independent pharmacies trade at 3x–5.5x EBITDA in 2025–2026, with the spread driven by prescription volume quality, revenue mix, regulatory history, and patient base transferability.

Low end — 3x–3.5x EBITDA: Pharmacies with heavy concentration in low-margin generic scripts, significant DIR fee exposure from Medicare Part D plans, declining patient counts, or any open DEA or state board investigations. Also pharmacies where the pharmacist-owner has personal relationships that may not transfer — patients who come in because they've known the owner for 20 years are a real transfer risk.

Mid range — 3.5x–4.5x EBITDA: The broadest category. Solid prescription volume, 8–12% EBITDA margins, documented patient base with a licensed pharmacist staying post-close at least 12 months, and reasonable PBM contract stack with manageable DIR exposure. This is where most independent pharmacies trade.

High end — 4.5x–5.5x EBITDA: Specialty or compounding pharmacies with revenues tied to long-term care, hospice, pain management, or specialty drug programs. These have higher margin scripts (specialty drugs can command 15–25%+ margin vs. 3–5% on generics), recurring patient relationships tied to chronic conditions, and documented systems that reduce key-person dependency. Buyers pay more because the revenue is stickier and the margin is structurally better.

Pharmacy valuations also use prescription file value as a distinct metric — separate from the going-concern EBITDA multiple. Understanding both matters for accurate deal pricing.

Prescription File Value: The Asset Buyers Are Actually Paying For

Most pharmacy acquisitions are structured as asset purchases, not stock purchases — and the primary asset is the prescription file, not the building, equipment, or inventory. Understanding how buyers value the prescription file gives you a clearer picture of the deal math.

The per-script valuation method. Buyers value prescription files based on active prescription count multiplied by a per-script rate. The industry benchmark range is $10–$35 per active script, with significant variation based on payer mix, script age, and patient loyalty indicators. A pharmacy with 12,000 active scripts at $15/script has a prescription file worth $180,000. At $25/script for a cleaner book, that's $300,000.

Active vs. total scripts. Active is typically defined as a prescription filled within the last 12 months. Older scripts count less or not at all. Buyers will pull a detailed script report during diligence and segment by recency, payer type, and therapeutic category.

Payer mix affects file value significantly. A file heavy in Medicare Part D and Medicaid is subject to DIR fees and lower dispensing fees — buyers price this in with lower per-script values. A file with 30%+ cash-pay or commercial insurance patients commands higher per-script values because the margin is better and the DIR risk is absent.

Why buyers care about patient loyalty. High refill rates (patients returning every 30 days for maintenance meds) indicate a stable, recurring revenue base. High patient acquisition rates with low refill rates suggest a transactional patient base that may not transfer.

For more on how independent pharmacies compare to chain-owned locations in valuation terms, see the independent pharmacy vs chain valuation guide.

SBA Financing for Pharmacy Acquisitions

Pharmacies are SBA 7(a) eligible, and the SBA is the primary financing vehicle for independent pharmacy acquisitions under $5M enterprise value. Here's how the financing actually structures.

Standard SBA deal on a $1.5M pharmacy acquisition: Buyer injects 10% ($150K), SBA lender covers 80–85% ($1.2M–$1.275M), seller carries 5–10% ($75K–$150K) as a standby note subordinated to the SBA loan for 24 months. Monthly debt service on a $1.2M SBA 7(a) loan at 10.5% over 10 years runs approximately $16,100/month ($193,200 annually). For the deal to clear 1.25x DSCR, the pharmacy needs $241,500+ in stabilized annual EBITDA after a market-rate pharmacist manager salary.

Inventory is handled separately. Pharmacy inventory (drug stock) is typically purchased at cost on top of the acquisition price. Buyers arrange a separate line of credit or use working capital to fund inventory, which can range from $50K for a small pharmacy to $300K+ for a high-volume operation. Don't model the inventory purchase price into your SBA loan — lenders separate this.

DEA registration transfers. The DEA registration is tied to the pharmacist-of-record and the physical location — not to the business entity. Buyers need to apply for a new DEA registration post-close, which typically takes 4–8 weeks. During this period, the selling pharmacist must remain available as the registered holder. This is a common source of closing delays that buyers should account for in their timeline.

State board of pharmacy license transfer. Each state has its own process. California requires a new pharmacy permit for the new ownership entity. Most states process this in 30–60 days with the right documentation. SBA lenders typically escrow a portion of the purchase price pending license transfer.

What Moves the Multiple: Pharmacy Valuation Drivers

The difference between 3x and 5x EBITDA on the same pharmacy revenue base comes down to a small number of measurable factors that buyers price very specifically.

Revenue mix: specialty and compounding vs. generic dispensing. Generic dispensing fees have been compressed by PBMs for a decade. A pharmacy generating 70% of revenue from generic fills at $8–$12 dispensing fees has thin, competitive margins. A pharmacy with 30%+ specialty or compounding revenue — HIV medications, oncology support, BHRT, pain compounding, long-term care programs — generates materially higher margins on those scripts and is priced accordingly.

DIR fees and PBM contract exposure. Direct and Indirect Remuneration (DIR) fees are the single largest discount driver in independent pharmacy valuations right now. Pharmacies with heavy Medicare Part D volumes on unfavorable PBM contracts can have 15–30% of their apparent EBITDA clawed back through DIR adjustments that arrive months after dispensing. Buyers who understand this haircut the EBITDA accordingly. Sellers who haven't quantified their DIR exposure are pricing their pharmacies based on phantom earnings.

Pharmacist-of-record continuity. If the selling pharmacist is the only licensed pharmacist in the building and plans to leave at close, the business needs an immediate licensed replacement — and that cost comes out of EBITDA. Buyers will require at minimum a 90-day pharmacist transition, and deals where the selling pharmacist stays 12 months under an employment agreement close at higher multiples than those where the buyer scrambles to recruit.

Regulatory history. Any open state board investigations, DEA letters, or CMS audits within the past 5 years will either kill the deal or substantially discount the price. Clean regulatory history is worth 0.5x–1.0x multiple.

Due Diligence: What to Audit Before You Close

Pharmacy due diligence is more intensive than most small business acquisitions because the regulatory and financial risks are both significant. Buyers should run through the following before signing a purchase agreement.

• Request a 24-month script-level data export: total fills, refill rates, payer mix, top therapeutic categories, and DIR fee adjustments by month
• Pull the last 3 years of PBM contract terms and reconciliation statements — identify any retroactive DIR fee adjustments and quantify the annualized impact on actual EBITDA
• Review DEA registration history: any Schedule II discrepancy investigations, Letters of Admonition, or controlled substance audit findings in the past 5 years
• Confirm state board of pharmacy license status and any active citations, complaints, or consent agreements
• Audit inventory for expired, recalled, or slow-moving stock — negotiate an adjustment to purchase price or inventory credit based on current saleable value
• Review all vendor contracts: drug wholesaler agreement (McKesson, Cardinal, AmerisourceBergen), POS and pharmacy management system, and delivery service agreements
• Confirm the lease assignment terms and remaining term — SBA lenders require the lease to extend through or be renewable for the loan term
• Validate the pharmacist staffing plan: who is the pharmacist of record post-close, what is their compensation, and what is their commitment length?

Finding Pharmacies for Sale: On-Market vs. Off-Market

Most independent pharmacy sales happen off-market or through pharmacy-specific brokers rather than general business broker networks. Understanding the sourcing channels matters for buyers who want to see the best opportunities before they're widely shopped.

Health care business brokers who specialize in pharmacy are the primary channel for listed deals. Firms like RxOwnership, Pharmacy Brokerage Services, and specialist health care M&A advisors typically handle the better-prepared pharmacy sales. General business brokers list pharmacies but often lack the technical knowledge to explain DIR exposure or DEA transfer mechanics to buyers.

Direct owner outreach works in pharmacy because many independent owners are retirement-age pharmacists who haven't engaged a broker yet. A direct letter or call to an independent pharmacy owner in a target market often finds sellers who are 12–24 months from wanting to exit but haven't started the process.

Buying a pharmacy from a chain closedown. When CVS, Walgreens, or Rite Aid close locations, they often sell the prescription files — not the real estate or fixtures — to local independents or buyers. These file purchases range from $50K to $500K depending on script count and can be a lower-entry way to acquire an established patient base and layer it into an existing pharmacy or new location.

For acquisition targets and deal flow in the pharmacy sector, see the pharmacy businesses for sale overview and the pharmacy acquisition multiples guide.